Optimized Identification of High-Grade Prostate Cancer by Combining Different PSA Molecular Forms and PSA Density in a Deep Learning Model
Authors:
- Francesco GentileFrancesco Gentile
- Matteo FerroMFMatteo Ferro
- Bartolomeo Della VenturaBVBartolomeo Della Ventura
- Evelina La CivitaECEvelina La Civita
- Antonietta LiottiALAntonietta Liotti
- Michele CennamoMCMichele Cennamo
- Dario BruzzeseDario Bruzzese
- Raffaele VelottaRaffaele Velotta
- Daniela TerraccianoDaniela Terracciano
Open Access
- 18 February 2021
- journal article
- research article
- Published by MDPI AG in Diagnostics
- Vol. 11 (2) , 335
Abstract
After skin cancer, prostate cancer (PC) is the most common cancer among men. The gold standard for PC diagnosis is based on the PSA (prostate-specific antigen) test. Based on this preliminary screening, the physician decides whether to proceed with further tests, typically prostate biopsy, to confirm cancer and evaluate its aggressiveness. Nevertheless, the specificity of the PSA test is suboptimal and, as a result, about 75% of men who undergo a prostate biopsy do not have cancer even if they have elevated PSA levels. Overdiagnosis leads to unnecessary overtreatment of prostate cancer with undesirable side effects, such as incontinence, erectile dysfunction, infections, and pain. Here, we used artificial neuronal networks to develop models that can diagnose PC efficiently. The model receives as an input a panel of 4 clinical variables (total PSA, free PSA, p2PSA, and PSA density) plus age. The output of the model is an estimate of the Gleason score of the patient. After training on a dataset of 190 samples and optimization of the variables, the model achieved values of sensitivity as high as 86% and 89% specificity. The efficiency of the method can be improved even further by training the model on larger datasets.Keywords
This publication has 47 references indexed in Scilit:
- Prostate Health Index (Phi) and Prostate Cancer Antigen 3 (PCA3) Significantly Improve Prostate Cancer Detection at Initial Biopsy in a Total PSA Range of 2–10 ng/mlPLOS ONE, 2013
- Prostate health index (phi) and prostate cancer antigen 3 (PCA3) significantly improve diagnostic accuracy in patients undergoing prostate biopsyThe Prostate, 2012
- Radical Prostatectomy versus Observation for Localized Prostate CancerNew England Journal of Medicine, 2012
- Outcome prediction for prostate cancer detection rate with artificial neural network (ANN) in daily routineUrologic Oncology: Seminars and Original Investigations, 2012
- Preoperative insulin‐like growth factor‐binding protein‐3 (IGFBP‐3) blood level predicts gleason sum upgradingThe Prostate, 2011
- Pre-analytical in-vitro stability of [-2]proPSA in blood and serumClinical Biochemistry, 2010
- Critical Review of Prostate Cancer Predictive ToolsFuture Oncology, 2009
- Standard Operating Procedures for Serum and Plasma Collection: Early Detection Research Network Consensus Statement Standard Operating Procedure Integration Working GroupJournal of Proteome Research, 2008
- Artificial neural network (ANN) velocity better identifies benign prostatic hyperplasia but not prostate cancer compared with PSA velocityBMC Urology, 2008
- Prostate-specific antigen and prostate cancer: prediction, detection and monitoringNature Reviews Cancer, 2008